The PI3-K-Akt pathway plays a central role in the development and progression of prostate cancer and other malignancies. We review original studies and summarize relevant sections of previous reviews concerning the relationships between abnormalities in the PI3-K-Akt pathway and prostate cancer progression. We discuss laboratory and clinical data that indicate gene perturbation and dysregulation of PI3-K-Akt pathway is common in prostate cancer and other malignancies. We further discuss the critical role of the PI3-K-Akt pathway in the oncogenic signaling network and provide examples that establish the PI3-K-Akt pathway as a focal point for the future development of informative biomarkers and effective therapies for prostate cancer.
Introduction
Prostate cancer remains the second leading cause of cancer mortality among American males. The predominant reason for such high and persistent mortality is the lack of curative therapies for androgen-resistant metastatic disease. An important observation from many prostate cancer studies is that disease progression is linked with the development of apoptosis resistance. The establishment and the continued growth of prostate cancer metastases involve overcoming multiple endogenous physiological barriers and therapeutic challenges, which normally induce an apoptotic response. It is critical to elucidate the cancer cell survival mechanisms that underlie the ultimate androgen-resistant state of prostate cancer and to develop informative biomarkers and effective therapies for this condition.
Recent studies indicate that phosphatidylinositol 3-kinase (PI3-K)-Akt pathway is a major survival pathway in human cancer and is central to the development and progression of specific malignancies (reviewed in Blume-Jensen and Hunter, 2001; 1 6 ). Akt was initially identified as an oncogene harbored within the AKT8 retrovirus isolated from a murine T-cell lymphoma 7 and was subsequently shown to be a proto-oncogene with a pleckstrin homology (PH) and serine/threonine kinase domains. Akt is also referred to as protein kinase B (PKB) since its catalytic domain is closely related to those of protein kinase A (PKA) and protein kinase C (PKC) family members. The kinase activity of Akt is stimulated by a variety of extracellular stimuli, such as growth factors, cytokines, chemokines, integrin engagement and T-cell receptor activation. The activation of Akt leads to the phosphorylation and regulation of a wide spectrum of its substrates involved in multiple cellular processes, including cell survival, cell growth, cell differentiation, cell cycle progression, cell proliferation and cellular metabolism. In this review, we will highlight the mechanisms of Akt regulation, the role of Akt in signal transduction, the genetic perturbations and dysregulation of the PI3-K-Akt pathway in prostate cancer and other malignancies. We will also discuss the potential for the development of informative molecular biomarkers for prostate cancer based on clinical correlates of the expression patterns of Akt and its downstream targets and the therapeutic potential of targeting the PI3-K-Akt pathway.
Mechanisms of Akt regulation
Akt is a family of serine/threonine kinases. The analysis of the domain structure revealed an N-terminal PH domain, a catalytic domain and a C-terminal regulatory domain for this protein family. In humans, the Akt family is composed of three highly homologous members named Akt1, Akt2, and Akt3. While expression of Akt3 is relatively tissue restricted, Akt1 and Akt 2 expression are widely distributed among various tissues. In unstimulated cells, Akt resides mainly in the cytosol. Following the activation of PI3-K by tyrosine kinase receptors or other cell surface receptors in response to ligands such as insulin, platelet-derived growth factor (PDGF), epidermal growth factor (EGF), or fibroblast growth factors (FGFs), the resulting second messenger, phospholipids phosphatidylinositol 3,4,5-trisphosphate (PI-3,4,5-P 3 ) or phosphatidylinositol 3,4-bisphosphate (PI-3,4-P 2 ), recruits Akt to the plasma membrane and binds to its PH domain. This binding leads to a conformational change of Akt, which is favorable for its phosphorylation at Thr308 in the kinase activation loop by 3-phosphoinositide-dependent kinase 1 (PDK1) and at Ser473 in the regulatory domain of the carboxylterminus by a yet unidentified kinase. A range of different candidates including integrin-linked kinase (ILK), MAPKAP kinase 2, conventional PKC isoforms, PDK1, and Akt itself have been proposed for this Ser473 kinase, but no single candidate seems to be indisputable. 8 Although phosphorylation at Thr-308 partially activates Akt, full activation of Akt requires phosphorylation on the second site (Ser473). Phosphorylated Akt (P-Akt) then dissociates from the plasma membrane and translocates to nucleus and other subcellular compartments to phosphorylate and regulate the function of many cellular proteins involved in cell proliferation, survival, motility and angiogenesis processes that are critical for tumorigenesis and metastasis. 3, 5, 9, 10 The primary consequence of PI3-K activation is the generation of phospholipids at the membrane, which function as second messengers to activate downstream kinases, including PDK1 and ILK. It is not clear whether ILK is an immediate upstream kinase of Akt. However, it is generally accepted that ILK functions as a regulator of Akt in response to integrin activation or growth factor stimulation. 11, 12 In normal mammalian cells the levels of PI-3,4,5-P 3 /PI-3,4-P 2 are tightly controlled by the combined effects of stringent PI3-K regulation and the action of several PI-3,4,5-P 3 /PI-3,4-P 2 phosphatases. Included in these phosphatases is the tumor-suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN), a 3-position lipid phosphatase, which converts PI-3,4,5-P 3 to PI-4,5-P 2 . The SHIP phosphatases (SHIP1 and SHIP2) also dephosphorylate PI-3,4,5-P 3 , but remove phosphate from the 5-position rather than the 3-position, creating PI-3,4-P 2 , which can still function as a second messenger to recruit PH-domain-containing proteins, including Akt, to the membrane leading to their subsequent activation. Therefore, although both PTEN and SHIP dephosphorylate PI-3,4,5-P 3 , PTEN apparently functions as the primary negative regulator of the PI3-K-Akt pathway. [13] [14] [15] [16] On the other hand, phosphorylation of Akt can also be controlled by serine/threonine protein phosphatases. [17] [18] [19] PP1 and PP2A are two major classes of serine/threonine protein phosphatases that are involved in many different cellular processes, including glycogen metabolism, cell cycle regulation, protein synthesis and intracellular transport, RNA splicing, and signal transduction. Specifically, many important signal transduction molecules, including Akt, are substrates of PP1 and PP2A. 18, 20, 21 Through dephosphorylation of these signal transduction regulators, PP1 and PP2A positively or negatively regulate multiple cellular signaling pathways. Several recent studies support an important role for PP2A in the regulation of the PI3-K-Akt pathway. PP2A was identified as the main phosphatase involved in the regulation of Akt in rat adipocytes. 22 It can be coprecipitated with Akt and coexpression of the catalytic subunit of PP2A with Akt inhibited Akt activity. 23 The activation of PP2A by N-ethylmaleimide, ceramide, palmitate or integrin a2b1 inhibits Akt phosphorylation. [23] [24] [25] [26] Conversely, the inhibition of PP2A by okadaic acid increases Akt activities. 21, 25, 26 Previously, we and others found that expression of caveolin-1 (cav-1), the major component of caveolae, is elevated in prostate cancer and other malignancies. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] To address the molecular mechanism of cav-1-mediated cell survival, we explored a possible link between cav-1 overexpression and Akt activation in prostate cancer cells. When we compared PI3-K-Akt signaling activities in cav-1-expressing LNCaP cells that had undergone adenoviral vector-mediated cav-1 gene transduction with PI3-K-Akt signaling activities in cav-1-negative vector control LNCaP cells, we found that Akt, but not PI3-K activities, were significantly higher in the former. The cells expressing cav-1 were also more resistant to programmed cell death after treatment with thapsigargin, which is known to induce apoptosis. This PI3-Kindependent Akt activation in cav-1 expressing cells was further confirmed by the determination of P-Akt half-life using the PI3-K-specific inhibitor LY294002. 41 These data suggested that cav-1 participates in the regulation of Akt by maintaining Akt in the activated (phosphorylated) form.
Since Akt and its direct upstream kinase PDK1 are substrates for serine/threonine protein phosphatases PP1 and PP2A, we investigated the possible involvement of PP1 and PP2A in cav-1-mediated maintenance of P-Akt. Interestingly, the catalytic subunits of PP1 and PP2A possess a previously described consensus cav-1 binding site. 42 Immunoprecipitation (IP) experiments demonstrated that cav-1 was present in the PP1 or Akt pathway in prostate cancer L Li et al PP2A IP complex and PP1 or PP2A was also present in the cav-1 IP complex, 41 suggesting that cav-1 associates with PP1 and PP2A. In vitro IP experiments using purified His-V5-human cav-1, PP1 (catalytic subunit) and PP2A (core enzyme) further demonstrated that cav-1 could bind to PP1 and PP2A outside of an intact cell context. Importantly, serine/threonine protein phosphatase activity assays using PP1 or PP2A IP complex or purified recombinant enzyme (PP1 catalytic subunit or PP2A core enzyme) indicated that interaction with cav-1 leads to the inhibition of PP1 and PP2A activities. 41 Reduced overall activities of PP1 and PP2A favor the maintenance of Akt phosphorylation and increased Akt activities.
To further demonstrate the roles of PP1 and PP2A in the regulation of Akt in prostate cancer, we incubated lysates from cav-1-expressing, LY294002-treated cells with various concentrations of purified PP1 or PP2A enzyme for 30 min at 301C in a protein phosphatase assay buffer with or without 1 mM MnCl 2 . Analysis of the phosphorylation status of Akt in cell lysates from cav-1 expressing cells in phosphatase assay buffer without MnCl 2 revealed that PP2A effectively dephosphorylates Akt at both S473 and T308 whereas PP1 is significantly less effective under the same conditions. Interestingly, in the presence of MnCl 2 PP1 efficiently dephosphorylates Akt at T308. Overall, our data indicate that both PP1 and PP2A can regulate the phosphorylation status of Akt, however, PP2A appears to be the predominant Akt phosphatase.
In summary, oncogenic signaling that stimulates Akt activities often involves extracellular growth or survival stimuli, such as hormones, growth factors or integrin activation. Subsequently, tyrosine receptor protein kinase activation can trigger the activity of PI3-K, which leads to PDK1 activation ( Figure 1 ). PDK1, and potentially other kinases, directly phosphorylate and activate Akt. PTEN functions as a major negative regulator in the PI3-K-Akt pathway through dephosphorylation of the PI3-K product PI-3,4,5-P 3 . Serine/threonine protein phosphatases PP1 and PP2A participate in the regulation of this pathway through dephosphorylation of Akt. In prostate cancer, cav-1 maintains activated Akt interaction with and inhibition, of PP1 and PP2A.
The role of Akt in signal transduction
Recent studies have revealed that Akt regulates a variety of cellular functions including cell survival, cell growth, cell differentiation, cell proliferation, cell cycle progres- Figure 1 Mechanisms of regulation of Akt. Stimulation of cells by extracellular stimuli such as hormones/growth factors results in the activation of PI3-K, triggering the production of PI-3,4,5-P 3 at the plasma membrane, which leads to activation of PDK1 and recruitment of Akt to the plasma membrane where it binds to PI-3,4,5-P 3 through its pleckstrin homology (PH) domain. This binding leads to a conformation change of Akt, that allows phosphorylation of Akt at Thr308 by PDK1 and at Ser473 by a yet unidentified kinase (putative candidates including ILK, MAPKAP kinase 2, conventional PKC isoforms, PDK1, and Akt itself). PTEN functions as a major negative regulator of the Akt pathway by converting PI-3,4,5-P 3 to PI-4,5-P 2 . PP1 and PP2A are also involved in the regulation of Akt activities through dephosphorylation of Akt. In prostate cancer cells, cav-1 maintains activated Akt through interaction with and inhibition of PP1 and PP2A. ). Peptide and protein library screening defined an optimal substrate motif for Akt as Arg-XaaArg-Xaa-Xaa-Ser/Thr, where Xaa is any amino acid. 44 Thus far, at least 24 Akt substrates containing such a motif have been identified.
One of the major functions of Akt in malignancy is promoting cancer cell survival. Cancer cells develop specific mechanisms to overcome apoptosis, or programmed cell death, which is a normal cellular function involved in the elimination of 'unnecessary' or damaged cells. Akt plays a central role in antiapoptotic pathways through phosphorylation and regulation of a variety of cell survival-related downstream targets ( Figure 2 ). For example, FKHR is a member of the Forkhead family of transcription factors that mediates transcription of specific proapoptotic genes such as BIM and FAS ligand. Phosphorylation of FKHR by Akt disrupts FKHRmediated transcription by promoting export of FKHR from nucleus to cytosol where it is sequestrated by the 14-3-3 protein. 45 BAD is a proapoptotic member of BCL-2 family proteins that promotes cell death by forming a nonfunctional heterodimer with the prosurvival molecule BCL-X L . Phosphorylation of BAD by Akt prevents the binding of BAD to BCL-X L , restoring BCL-X L 's antiapoptotic function. 46 Akt can also inhibit the conformational change and mitochondrial translocation of BAX, another proapoptotic member of BCL-2 family proteins, thus preventing the disruption of mitochondrial membrane potential and the activation of caspase 3. 47 Caspase 9 is an important effector caspase in the mitochondrial death pathway. Phosphorylation of procaspase 9 by Akt abrogates cytochrome c-induced proteolytic processing of procaspase 9, which in turn prevents the activation of downstream executor caspases. 48 CREB is a group of transcription factors that modulate the expression of genes containing promoters with cyclic AMP response elements. Activation of CREB by Akt phosphorylation triggers recruitment of the coactivator CREB-binding protein (CBP) 49 and promotes transcription of specific prosurvival genes such as BCL-2. 50 The NF-kB transcription factor promotes cell survival in response to several apoptotic stimuli. Phosphorylation and activation of its positive regulator IkB kinase by Akt leads to phosphorylation and degradation of IkB, an inhibitor of NF-kB, promoting nuclear translocation of NF-kB and activation of its target genes. 51 GSK3b is known not only as a kinase for glycogen synthesis but also as a regulator for several signaling pathways because of its kinase activities for a variety of downstream targets including c-Myc, b-catenin, CREB, and NF-kB that are often found to be overexpressed in multiple types of cancers. Inactivation of GSK3b by Akt phosphorylation favors increased protein levels or kinase activities of these gene products that affect cell survival through diverse mechanisms. 52 A more recently identified Akt substrate is apoptosissignal-regulating kinase (ASK1), which stimulates the activation of MAP kinase that activates p38 MAP kinase and JNK. Phosphorylation and inhibition of ASK1 results in reduced JNK activity. 53 In some systems JNK promotes apoptosis, and therefore, in this context, inactivation of ASK1 by Akt phosphorylation favors cell survival. Akt can also influence the activity of tumorsuppressor p53 through phosphorylation of the oncoprotein MDM2. MDM2 is a p53 target gene; however, the MDM2 protein, in turn, binds the p53 transactivation domain and promotes p53 degradation, leading to inhibition of transcription of p53 target genes involved in cell cycle arrest and apoptosis. Phosphorylation and activation of MDM2 by Akt promotes translocation of MDM2 to the nucleus, where it binds and inhibits p53. 54 Moreover, Akt was reported to upregulate the expression of insulin-like growth factor I receptor (IGF-IR), leading to enhanced cell survival activities and invasiveness in human pancreatic cancer cells. 55 Akt activation may also contribute to tumor invasion and metastasis by stimulating secretion of matrix metalloproteinase 9. 56 It is of interest that Akt also mediates VEGF-stimulated endothelial cell proliferation. 57 Importantly, our studies in prostate cancer cells showed that cav-1-mediated maintenance of activated Akt leads to increased phosphorylation of multiple downstream targets, including GSK3a/b, FKHRL, and MDM2. 41 All of these three proteins play important roles in cancer cell survival as discussed above.
Another interesting finding from our studies in prostate cancer cells is that the expression of cav-1 in cav-1-negative LNCaP cells led to significantly increased nuclear translocation of phosphorylated androgen receptor (AR) at both ablation (5 pM) and physiological (5 nM) androgen concentrations, suggesting a potential role for cav-1 in regulation of AR nuclear translocation. AR has been one of major focuses in studies of normal and abnormal prostate growth. 58, 59 Although the general molecular mechanisms of androgen action have been established, the discovery of specific molecular pathways that lead to precise regulation of AR in either androgendependent or -independent manners is still a critical area of research in normal prostate function and in prostate cancer. Interestingly, two recent reports indicated that AR contains two Akt phosphorylation consensus sequences (RXRXXS/T), 9 located at S213 (RAREAS) and S791 (RMRHLS), and both were shown to be phosphorylated by Akt in vitro. 60, 61 However, a screen of phosphorylation sites on AR in COS-1 cells using a combination of peptide mapping, Edman degradation, and mass spectrometry led to the identification of seven other phosphorylation sites on AR, but not Akt phosphorylation sites at S213 and S791. 62 Although the question of whether AR is a physiological substrate for Akt remains unresolved, our results showing increased nuclear translocation of phosphorylated AR by cav-1 provides new insight into the role of cav-1 in hormone-resistant and progressive prostate malignancies. In an independent study, physical interaction of cav-1 and AR was observed. 63 One explanation for the increased nuclear translocation of AR is that the interaction with cav-1 may result in an AR conformational change that favors ligand binding and/or nuclear translocation.
AR is also regulated by specific nuclear coactivator proteins. [64] [65] [66] [67] Recent studies have shown that in a significant number of prostate cancer tissues (47%), nuclear receptor coactivator SRC-3 (PCIP, ACTR, RAC3, AIB1, and TRAM-1) is overexpressed compared to normal prostate tissues 68 69 This conclusion is further supported by analysis of SRC-3 null mutant mice, which are smaller in size and demonstrate lower levels of Akt expression and activity compared to wild-type littermates. 69 Thus SRC-3 overexpression in human prostate cancer is likely to lead to higher levels of Akt activation.
Akt exerts its role in cancer cell proliferation/tumor growth through phosphorylation and regulation of numerous signaling molecules involved in cell cycle regulation and angiogenesis (Figure 2) . The tumorsuppressor p21
WAF1 is a p53 target gene that functions as a cell cycle inhibitor following induction by p53 in response to specific cell stress signals such as DNA damage. Phosphorylation by Akt prevents nuclear localization of p21 WAF1 , separating it from its cyclindependent kinase targets. Thus, Akt activation abrogates p21 WAF1 -mediated cell cycle arrest. 70 Moreover, cytoplasmic p21 WAF1 binds to ASK1 and blocks its apoptotic function. Similarly, phosphorylation of p27 Kip1 by Akt leads to cytoplasmic retention of this cell cycle inhibitor and its sequestration by 14.3.3 scaffold protein. 71 The Akt-mediated reduction of free p27
Kip1 protein levels is associated with growth acceleration of prostate xenograft tumors. 72 Phosphorylation and inhibition of GSK3b by Akt abolishes phosphorylation of cytoplasmic signaling molecule b-catenin, causing its stabilization and nuclear translocation, where it associates with T-cell factor (TCF)/lymphocyte enhancing-binding factor-1 (LEF-1) to induce the transcription of several genes, including cyclin D1, that promote cell cycle progression through hyperphosphorylation and inactivation of the retinoblastoma (Rb) tumor-suppressor protein. 73 Phosphorylation of MDM2 promotes its translocation to the nucleus where it binds and inhibits p53 activities towards cell cycle regulation. 54 mTOR (the mammalian target of rapamycin) is a serine/threonine kinase that regulates cell growth by activating p70 ribosomal S6 kinase (RSK), which promotes the translation of mRNA with 5 0 polypyrimidine tracts, and by inhibiting 4E-BP1, which acts as a translational inhibitor of mRNAs bearing a 5 0 CAP structure. 6 mTOR also regulates transcription of cMyc and activation of Star 3, PKCa, and PKCd, that are involved in tumorigenesis. 1, 74 Phosphorylation by Akt activates mTOR and thus enhances cell growth. The breast cancer susceptibility-1 (BRCA1) gene encodes a nuclear phosphoprotein that plays a role in DNA repair. Phosphorylation by Akt impairs its nuclear localization and tumor-suppressor function. 75 Activation of Akt can also enhance tumor angiogenesis. Loss of PTEN in prostate cancer is associated with increased microvessel density in prostate cancer tissue, consistent with increased angiogenesis. Activated Akt in prostate cancer cells can increase expression of HIF-1a and its transcriptional targets such as VEGF. In addition, Akt can have actions within endothelial cells that promote angiogenesis. Endothelial nitric oxide synthase (eNOS) is the nitric oxide synthase isoform responsible for maintaining systemic blood pressure, vascular remodeling and angiogenesis. Phosphorylation of eNOS by Akt leads to production of NO and enhances angiogenesis. 76 ,77 ILK appears to be important in regulating angiogenesis via Akt activation through both of these mechanisms. Thus, inhibition of Akt activity is a potential antiangiogenic therapeutic strategy.
In summary, through phosphorylation and regulation of a wide spectrum of substrates such as FKHR, GSK3, MDM2, BAD, caspase 9, p27, p21, mTOR, IKKa/b, and eNOS, Akt promotes tumor cell survival, proliferation, angiogenesis, and metastasis ( Figure 2) . Interestingly, recent studies of prostate cancer have revealed common molecular regulators of AR and Akt, indicating that an expanding number of signaling pathways involved in tumorigenesis and cancer progression involve Akt.
Genetic perturbation and dysregulation of the PI3-K-Akt pathway
Akt is constitutively active in many human cancers due to amplification of the Akt gene or as a result of amplification/mutation in components of the signaling pathway that regulates Akt activities ( 84 and breast cancer. 80, 85 Elevated Akt expression and kinase activities are associated with a hormone-resistant phenotype and correlates with a poor prognosis in human prostate cancer and breast cancer. 78, 79, 85, 86 Upstream of Akt, amplification of PI3-K has been reported for prostate, 79 ovarian, 87, 88 colon, 88 and breast cancer. 85 Several protein-tyrosine kinases (PTKs), which act upstream of the PI3-K and are important regulators of the PI3-K-Akt pathway, have been found overexpressed in various cancers because of activating mutations or other genetic alterations. For example, FGFR1 is overexpressed in localized prostate cancer and amplified in hormone-resistant prostate cancers;
79 ErbB2/HER2/Neu is overexpressed in prostate, breast, ovarian, gastric, nonsmall lung and colon cancers; [89] [90] [91] [92] IGF-1R expression ). In prostate cancer, at least three mechanisms have been identified for functional loss of PTEN: chromosome deletion or loss of heterozygosity (LOH), [96] [97] [98] [99] [100] [101] somatic mutations 95, [99] [100] [101] [102] [103] and epigenetic aberrations. 104, 105 The majority of human prostate cancer cell lines and xenografts that have been evaluated show inactivation of the PTEN tumor-suppressor gene. The extent to which PTEN is inactivated in human prostate cancer in vivo is not completely certain since a simultaneous, comprehensive, large-scale analysis of PTEN LOH, homozygous deletion, mutation, and protein expression in the various clinical stages of prostate cancer has not been reported. The PTEN tumor-suppressor gene maps to human chromosome 10q23.3 and LOH at this locus has been detected in 25-30% of clinically localized human prostate cancers, although mutation or homozygous deletion of the PTEN gene is detected in approximately 10% of these same cases (for review, see Ittmann, 1998 94 ). Immunohistochemical studies reveal complete loss of PTEN protein expression in 15-20% of clinically localized prostate cancers, with a substantial fraction of cases showing decreased expression. Thus, although it cannot be known with certainty due to the fragmentary nature of these studies, at least 20% of localized cancers have complete loss of PTEN activity due to loss of protein and/or inactivating point mutations. An additional 10-20% had LOH at the PTEN locus without complete inactivation. Such LOH without biallelic inactivation is probably clinically significant, since it has been shown in the TRAMP mouse model of prostate cancer that loss of a single PTEN allele is associated with more rapid cancer progression, metastasis, and death. Similarly, LOH at 10q23 is present in more than 50% of metastatic prostate cancers while biallelic PTEN inactivation is present in 30% of such cases. 94 Given that a significant fraction of men either present with or ultimately develop metastatic prostate cancer, it is likely that complete or partial loss of the PTEN gene plays a role in approximately 40-50% of human prostate cancers overall. Loss of PTEN has been found associated with hormone-refractory, 106 and advanced stage prostate cancer. 98, 107, 108 In the past few years, the results of multiple studies have shown that PP2A or PP1 can participate in the regulation of PI3-K-Akt pathway through dephosphorylation of activated Akt and that these proteins can function as the major phosphatases for Akt in some systems. [21] [22] [23] [24] [25] [26] Recent studies also show that alteration of PP2A and PP1 gene expression is associated with multiple human cancers. The PP2R1B gene that encodes the b isoform of the A subunit of PP2A is located in a region showing high-frequency LOH. 109 Mutations in the gene encoding the A subunit of PP2A have been found in human breast, lung, colon and colorectal carcinomas, and melanomas. 109, 110 These mutations display defective or decreased binding to C subunit or B subunit of PP2A and therefore impair the normal functions of PP2A. 109, 111, 112 In addition, expression of the PP2A subunit Bg gene was found to be suppressed in human melanoma. 113 All of these findings support the notion that PP2A may function as a tumor-suppressor gene. Although the role of PP1 in tumorigenesis is not as evident as PP2A, it has been reported that PP1 interacts with and dephosphorylates the Rb tumor-suppressor protein returning Rb to its growth suppressive state (reviewed in Tamrakar et al, 2000 114 ), and genetic alterations in PP1 have been identified in human cancers. 115, 116 In prostate cancer, especially in advanced prostate cancer, overexpression of cav-1 is frequently observed. 29, [37] [38] [39] [40] Our finding of cav-1 interaction with and inhibition of two major serine/threonine protein phosphatases, PP1 and PP2A, establishes an important link between cav-1 and Akt, that is, cav-1 compromises PP1 and PP2A activities and thus favors the maintenance of Akt in its active (phosphorylated) form.
In summary, increased Akt activities in prostate cancer and other malignancies are often due to amplification of the Akt gene or its upstream kinases, such as PI3-K and protein tyrosine kinases, or deletion/mutation of negative regulators of this pathway, such as PTEN, PP2A, and PP1. In prostate cancer, especially in advanced prostate cancer, elevated levels of cav-1 may play an important role in limiting PP2A and PP1 activities, leading to the maintenance of activated Akt.
Molecular biomarkers based on Akt activities
The active phosphorylated form of Akt is an excellent prognostic marker for prostate cancer. Using tissue microarray technology in a large cohort of patients, we have identified that a high level of P-Akt in prostate cancer was predictive of a higher probability of recurrence on univariate and multivariate analysis with hazard ratios considered high on semiquantitative analysis. 117 Since most patients fall within the Gleason 6 and 7 categories, and because of the known limitations of Gleason scoring, we tested P-Akt for its predictive capacity within the subgroup. We found that P-Akt level is also an independent prognostic indicator of survival when Gleason 6 and 7 patients were analyzed separately. Surprisingly, a high level of P-Akt in non-neoplastic tissues is also an independent predictor of biochemical recurrence.
Numerous targets of P-Akt have also been tested in this same patient cohort, including GSK3, FHKR and p27. Proliferation and apoptosis end points were analyzed using Ki67 and TUNEL. Other markers that were related to, or potentially related to, Akt signaling including PTEN, NF-kB, VEGFR3, ASCT2, ERa, AR, DAX-1, TIF, SRC-3, SRC-1, and Sprouty were also tested. Cox modeling was used to identify the best combination of markers to predict PSA recurrence. We identified a number of significant predictors for PSA recurrence-free survival in prostate cancer, which were used to construct a multivariate predictive model. The set of tissue biomarkers significantly (Po0.001) improved the commonly used clinical-pathological model of prediction and mostly included P-Akt and its targets. Overall, we have demonstrated an incremental trend of improved (Ayala unpublished data) . In summary, tissue microarray studies and immunohistochemical studies of prostate cancer have established a positive correlation between P-Akt and clinical markers of progression. Importantly, P-Akt is also an independent predictor of biochemical recurrence. The development of molecular biomarkers based on Akt activities will provide insight into tumor progression, and clinically useful information for prostate cancer treatment.
Therapeutic potential of targeting the PI3-K-Akt pathway P-Akt is upregulated in a significant number of different types of malignancies including prostate cancer. The results from intensive studies of the PI3-K-Akt pathway have firmly established a central role for Akt in tumorigenesis and cancer progression and have exposed the PI3-K-Akt pathway as a promising therapeutic target.
Efforts have been made to develop small-molecule kinase inhibitors targeting PI3-K. The first generation compounds, such as wortmannin and LY294002, which inhibit the p110 catalytic subunit of PI3-K, have been widely used in vitro for years, but little progress has been made in clinical application. Wortmannin, which has a short half-life, is not an acceptable pharmaceutical candidate. The administration of LY294002 in mouse tumor models has been shown to confer antitumor activity and to enhance the efficacy of the chemotherapeutic agent paclitaxel with modest side effects. 118 However, a concern that has arisen is the specificity of this inhibitor, since it apparently acts against all the p110 isoforms as well as more distant PI3-K-like kinases such as ATM and ATR. 6 An alternative and potentially more specific approach is to inhibit the phosphotyrosine binding of Src homology 2 (SH2) domain in p85 regulatory subunit of PI3-K, preventing the recruitment and activation of PI3-K by receptor tyrosine kinases. It was demonstrated that small peptidomimetics derived from the primary sequence of the phosphotyrosine motif in the platelet-derived growth factor-b (PDGF-b) receptor blocks the association of the C-terminal SH2 domain of the p85 subunit of PI3-K to PDGF-b receptor. 119 Akt itself is an attractive therapeutic target. A potentially powerful strategy is to block the binding of PH domain of Akt to PI-3,4,5-P 3 or PI-3,4-P 2 , thus preventing its membrane translocation and activation by PDK1. Novel PI analogs have been shown to inhibit Akt effectively in cell culture. 120 The 3D structural determination of the Akt PH domain, 121 also provides valuable information for researchers to design specific inhibitors of this kinase as potential antitumor agents. This type of drug may be more specific since different PH domains among AGC family kinases normally share o20% sequence identity, allowing for the development of drugs that bind specifically to the PH domain of Akt. 122 On the other hand, the effectors that regulate and activate Akt activity may be also 'drugable'. For example, the elevated cav-1 in prostate cancer favors the maintenance of activated Akt, 41 and therefore targeting cav-1 provides an alternative approach to suppressing Akt activity in prostate cancer cells. Since cav-1 is secreted by prostate cancer cells and can be detected in the serum of prostate cancer patients, 123 ,124 using a specific antibody to neutralize cav-1 may be therapeutically useful. In a mouse model of metastatic prostate cancer, cav-1 antibody therapy was shown to suppress orthotopic tumor growth and metastasis. 124 In addition to cav-1 antibody, cav-1 SiRNA may also serve as a useful tool to disrupt cav-1 function in cancer cells.
Drug targets can also be selected from specific Akt substrates that are involved in tumorigenesis, such as FKHR, BAD, and mTOR. The binding of 14-3-3 protein to FKHR or BAD could potentially be disrupted by peptidomimetics or small molecules, thus favoring proapoptotic functions of these proteins. Targeting mTOR has been a focus over the past few years. 6, 43, 125 Rapamycin, an inhibitor of mTOR kinase, and its analogs CCI-779 and RAD001 have been shown to have significant in vitro and in vivo antiproliferative activity against a broad range of human cancers. [126] [127] [128] [129] Several rapamycin analogs have already been approved for use in transplant patients as immunosuppressants.
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RAD001 and CCI-779 are currently in phase I and II trials, respectively, as anticancer agents. 125 The PI3-K-Akt pathway appears to be a promising therapeutic target for cancer treatment. However, as this pathway is also involved in multiple cellular processes of normal cells, a reasonable therapeutic index is a significant challenge for future drug development. Hopefully, the continued search for new inhibitors of this pathway will lead to the discovery of a new generation of inhibitors that eliminate the pitfalls of the first generation inhibitors. Maximum antitumor efficacy and minimum side effects may ultimately be achieved through the combination of specific PI3-K-Akt pathway inhibitor with others different types of cancer therapeutic agents.
In summary, because of its central role in tumorigenesis, the PI3-K-Akt pathway represents a promising source of therapeutic targets for cancer treatment. Significant progress has been made in developing small-molecule kinase inhibitors targeting PI3-K, the PH domain of Akt, or specific Akt downstream targets, such as FKHR, BAD, and mTOR. In prostate cancer, targeting cav-1 through specific antibodies cav-1 or SiRNA may prove to be useful in cancer treatment.
Future perspective
The results from more than a decade of research focused on the PI3-K-Akt pathway have firmly established a central role of Akt in tumorigenesis and cancer progression. For prostate cancer, significant progress has been made in the development of biomarkers based on P-Akt and Akt downstream targets and in the exposure of the PI3-K-Akt pathway as a source of therapeutic targets. Looking forward, final identification, purification, and cloning of the elusive Ser473 kinase will provide the missing piece of PDK2 in the Akt activation puzzle. The development of proteomics technology will hopefully allow the unambiguous identification and clarification of Akt substrates and new information regarding the Akt pathway in prostate cancer L Li et al phenotypes of mice lacking different isoforms of Akt will increase our understanding of the functional significance of the PI3-K-Akt pathway. The development of molecular biomarkers based on Akt activities should greatly inform therapeutic decisions. The discovery of new and more specific inhibitors of this pathway will hopefully eliminate the pitfalls of current generation inhibitors. For example, tissue-specific delivery of SiRNAs that target the PI3-K-Akt pathway or the delivery of negative regulators of the PI3-K-Akt pathway such as PTEN, PP2A via a DNA or protein format are promising approaches for cancer therapy. For prostate cancer, targeting cav-1 with specific antibodies or cav-1 SiRNA may prove therapeutically useful. Ultimately, maximum antitumor efficacy and minimum side effects will likely be achieved by using specific combinations of PI3-K-Akt pathway inhibitors and other standard types of cancer therapeutic agents. Successes using small-molecule kinase inhibitors against BCR-ABL in chronic myelogenous leukemia, c-KIT in gastrointestinal stromal tumors, and EGFR in lung cancer, in addition to the rapid development of new therapeutic techniques, such as SiRNA, and new methods for DNA or protein delivery, cause us to be optimistic about the future clinical success of drugs targeting the PI3-K-Akt pathway for cancer treatment.
